FDA extends DTC guidance comment period
Executive Summary
FDA reopens comment period for draft guidances on direct-to-consumer advertising until Aug. 10. "We got comments that folks wanted more time to do DTC research, complete DTC research and also more time to provide comments," Ad Division Director Tom Abrams said during a DIA audioconference May 27. The agency also plans to conduct its own research on the content and format of the brief summary. FDA released the DTC guidances Feb. 4 (1"The Pink Sheet" Feb. 9, 2004, p. 3)...
You may also be interested in...
FDA Releases DTC Guidances; “Not The Last Word” On Ads, McClellan Says
FDA's publication of three draft guidances on direct-to-consumer advertising is unlikely to relieve pressure on the agency to explain its approach to enforcement actions against drug manufacturers that repeatedly run false and misleading promotions
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.